inclusion criteria: 1. patients must exhibit symptoms of covid-19 disease at screening; 2. patients must be 18 years of age or older, of either gender; 3. patients must have a documented sars-cov-2 rna-positive test virus within 3 days prior to randomization; 4. patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for covid-19 disease; 5. patient's health status must be 3 (if hospitalized for comorbidities), 4, or 5 on the who clinical progression scale defined as hospitalized moderate disease (no oxygen therapy or oxygen by mask or nasal prongs); 6. if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. 7. patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; 8. patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; 9. patients must be able to swallow the study drug capsules

inclusion criteria: 1. patients must exhibit symptoms of covid-19 disease at screening; 2. patients must be 18 years of age or older, of either gender; 3. patients must have a documented sars-cov-2 rna-positive test virus within 3 days prior to randomization; 4. patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for covid-19 disease; 5. patient's health status must be 3 (if hospitalized for comorbidities), 4, or 5 on the who clinical progression scale defined as hospitalized moderate disease (no oxygen therapy or oxygen by mask or nasal prongs); 6. if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. 7. patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; 8. patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; 9. patients must be able to swallow the study drug capsules

inclusion criteria: patients must exhibit symptoms of covid-19 disease at screening; patients must be 18 years of age or older, of either gender; patients must have a documented sars-cov-2 rna-positive test virus within 3 days prior to randomization; patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for covid-19 disease; patient's health status must be 3 (if hospitalized for comorbidities), 4, or 5 on the who clinical progression scale defined as hospitalized moderate disease (no oxygen therapy or oxygen by mask or nasal prongs); if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; patients must be able to swallow the study drug capsules

inclusion criteria: patients must exhibit symptoms of covid-19 disease at screening; patients must be 18 years of age or older, of either gender; patients must have a documented sars-cov-2 rna-positive test virus within 3 days prior to randomization; patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for covid-19 disease; patient's health status must be 3 (if hospitalized for comorbidities), 4, or 5 on the who clinical progression scale defined as hospitalized moderate disease (no oxygen therapy or oxygen by mask or nasal prongs); if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; patients must be able to swallow the study drug capsules

inclusion criteria: 1. patients must exhibit symptoms of covid-19 disease at screening; 2. patients must be 18 years of age or older, of either gender; 3. patients must have a documented sars-cov-2 rna-positive test virus within 3 days prior to randomization; 4. patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for covid-19 disease; 5. patient's health status must be 3 (if hospitalized for comorbidities), 4, or 5 on the who clinical progression scale defined as hospitalized moderate disease (no oxygen therapy or oxygen by mask or nasal prongs); 6. if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. 7. patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; 8. patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; 9. patients must be able to swallow the study drug capsules

inclusion criteria: 1. patients must exhibit symptoms of covid-19 disease at screening; 2. patients must be 18 years of age or older, of either gender; 3. patients must have a documented sars-cov-2 rna-positive test virus within 3 days prior to randomization; 4. patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for covid-19 disease; 5. patient's health status must be 3 (if hospitalized for comorbidities), 4, or 5 on the who clinical progression scale defined as hospitalized moderate disease (no oxygen therapy or oxygen by mask or nasal prongs); 6. if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. 7. patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; 8. patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; 9. patients must be able to swallow the study drug capsules

inclusion criteria: 1. patients must exhibit symptoms of covid-19 disease at screening; 2. patients must be 18 years of age or older, of either gender; 3. patients must have a documented sars-cov-2 rna-positive test virus within 3 days prior to randomization; 4. patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for covid-19 disease; 5. patient's health status must be 3 or 4 on the world health organization (who) ordinal scale for clinical improvement* defined as hospitalized mild disease (no oxygen therapy or oxygen by mask or nasal prongs); 6. if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. 7. patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; 8. patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; 9. patients must be able to swallow the study drug capsules

inclusion criteria: 1. patients must exhibit symptoms of covid-19 disease at screening; 2. patients must be 18 years of age or older, of either gender; 3. patients must have a documented sars-cov-2 rna-positive test virus within 3 days prior to randomization; 4. patients must be admitted (or under observation to be admitted) to a controlled facility or hospital to receive standard-of-care for covid-19 disease; 5. patient's health status must be 3 or 4 on the world health organization (who) ordinal scale for clinical improvement* defined as hospitalized mild disease (no oxygen therapy or oxygen by mask or nasal prongs); 6. if female, must be either post-menopausal (one year or greater without menses), surgically sterile, or, for female subjects of child-bearing potential who are capable of conception, must be: practicing a highly effective method of birth control during the study and through 30 days after the last dose of the study medication. 7. patients must have the ability to understand and give informed consent, which can be verbal with a witness, according to local requirements; 8. patients deemed capable of adequate compliance including attending scheduled visits for the duration of the study; 9. patients must be able to swallow the study drug capsules